SCHEMBL5847664

SCHEMBL5847664

Cc1cccc(-c2c(-c3ccnc(Cl)c3)nc(Cl)n(C)c2=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.49
MAP4K4 O95819 1/20 0.43
FRK P42685 1/20 0.43
MAPK9 P45984 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CSNK1D P48730 1/20 0.43
CDC42BPA Q5VT25 1/20 0.43
MINK1 Q8N4C8 1/20 0.43
MAP4K5 Q9Y4K4 1/20 0.43
TGFBR1 P36897 3/20 0.41
TDP2 O95551 1/20 0.40
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
ADORA2A P29274 2/20 0.39
TP53 P04637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPT P10636 2/20 0.38
MAT2A P31153 1/20 0.38
PTPN11 Q06124 1/20 0.38
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5786878 0.92 MAPK14 (0.50) MAPK14MAP4K4FRKMAPK9CSNK1A1
SCHEMBL5787744 0.87 CSNK1D (0.55) MAPK14MAP4K4FRKMAPK9CSNK1A1
SCHEMBL5788570 0.76 MAPK14 (0.53) MAPK14TGFBR1ADORA2AADORA1
SCHEMBL5848168 0.76 MAPK14 (0.39) MAPK14MAP4K4FRKMAPK9CSNK1A1
SCHEMBL6506836 0.75 MAPK14 (0.58) MAPK14MAP4K4PIM1PIM2ADORA2A
SCHEMBL5847952 0.74 MAPK9 (0.43) MAPK14MAP4K4FRKMAPK9CSNK1A1
SCHEMBL5786760 0.73 ADORA2A (0.63) MAPK14ADORA2AADORA1
SCHEMBL5786467 0.73 MAPK14 (0.44) MAPK14TGFBR1MAPTPTPN11LMNA
SCHEMBL5788934 0.71 GRIN1 (0.45) MAPK14MAP4K4FRKMAPK9CSNK1A1
SCHEMBL27507564 0.71 MAPK9 (0.49) MAPK14MAP4K4FRKMAPK9CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026326-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-04-11 US disclosed
US-20050038010-A1 Substituted heterocyclic compounds and methods of use AMGEN, INC. 2005-02-17 US disclosed
EP-1506186-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2005-02-16 EP disclosed
WO-2003099808-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038010-A1 Substituted heterocyclic compounds and methods of use MYLK2, MYLK, MCL1 MAPK14 2458/4885MAP4K4 1286/4885FRK 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.